Open Access

Endocrine control of canine mammary neoplasms: serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors

  • Michèle Spoerri1, 2,
  • Franco Guscetti3,
  • Sonja Hartnack4,
  • Alois Boos2,
  • Christine Oei5,
  • Orsolya Balogh1,
  • Renata M Nowaczyk6,
  • Erika Michel1,
  • Iris M Reichler1 and
  • Mariusz P Kowalewski2Email author
Contributed equally
BMC Veterinary Research201511:235

https://doi.org/10.1186/s12917-015-0546-y

Received: 1 May 2015

Accepted: 21 August 2015

Published: 15 September 2015

Abstract

Background

Neoplasms of the mammary gland are among the most common diseases in female domestic dogs (Canis familiaris). It is assumed that reproductive hormones influence tumorigenesis in this species, although the precise role of the endocrine milieu and reproductive state is subject to continuing discussion. In line with this, a recent systematic review of available data on the development of mammary neoplasms revealed weak evidence for risk reduction after neutering and an effect of age at neutering. Investigation of several hormone receptors has revealed decreased expression of estrogen receptor-alpha (ERα, ESR1), progesterone (P4) receptor (PGR), prolactin (PRL) receptor (PRLR) and growth hormone receptor (GHR) associated with neoplastic differentiation of mammary tissues. In other studies, increased levels of estrogens, progesterone and prolactin were found in serum and/or tissue homogenates of dogs with malignant neoplasms. However, the association between these entities within one animal population was never previously examined. Therefore, this study investigated the association between circulating serum concentrations of estradiol-17β, progesterone and prolactin, and gene expression of ERα (ESR1), ERβ (ESR2), PGR, PRLR, PRL and GHR, with respect to reproductive state (spayed vs. intact) and cycle stage (anestrus vs. diestrus). Additionally, the expression of E-cadherin (CDH-1) was evaluated as a possible indicator of metastatic potential.

Results

For all receptors, the lowest gene expression was found in malignant tumors compared to normal tissues of affected dogs. Steroid levels were not influenced by their corresponding receptor expression in mammary neoplasms, but increased PRL levels were negatively associated with low PRLR gene expression in malignant tumors. The expression of CDH-1 was influenced by tumor malignancy and cycle stage, i.e., the highest gene expression was found in benign mammary tumors in diestrous dogs compared to normal and malignant mammary tissues of anestrous and spayed dogs.

Conclusions

Herein, it has been confirmed that transformation towards malignant neoplasms is associated with significant reduction of gene expression of particular hormone receptors. Only PRLR in malignant tumors seems to be influenced by circulating PRL levels. In dogs, CDH-1 can be used as a prognostic factor; its expression, however, in benign tumors is influenced by cycle stage.

Keywords

Dog Mammary neoplasm Sex hormones Hormone receptors

Background

Estrogens (estradiol 17β; E2), progesterone (P4), prolactin (PRL) and growth hormone (GH) are essential for physiological mammary growth and development, which not only take place during pregnancy but also occur with every reproductive cycle. While estrogens induce ductal growth, P4 is essential together with PRL for lengthening and tertiary branching of the ductal system and stimulation of lobulo-alveolar development [1, 2]. Furthermore, PRL promotes changes of the alveolar cells towards a secretory type and induces lactation [14]. The effects of these hormones are mediated through binding to their respective receptors within the mammary gland. Changes in the expression of E2, P4 and GH receptors (ER, PGR and GHR, respectively) but not of prolactin receptors (PRLR) have been described in normal canine mammary tissue during different phases of the estrous cycle [58]. In addition to physiological changes in the mammary gland during the estrous cycle, different pathological changes may occur. Tumors are considered to be the most common disorders of the mammary gland in dogs. Reproductive state and the endocrine milieu seem to play a pivotal role in the development of canine mammary tumors (CMT). The sparing effect of early spaying on CMT formation has been known since the work of Schneider and colleagues in 1969 [9]. However, a recent systematic review of peer-reviewed journal articles concluded that the evidence for a reduced CMT risk following ovariohysterectomy, as well as for an influence of age at neutering, is weak [10]. Studies investigating the impact of spaying, performed concurrently or shortly before the time of mammary tumor surgery, on disease-free interval or survival time yielded inconsistent results, showing either a beneficial effect of ovariohysterectomy or no effect [1115]. Yet, a role for E2 in mammary tumorigenesis was suggested by its higher blood levels in dogs with malignant neoplasms compared to those without tumors [1618]. On the other hand, bitches with inflammatory mammary carcinoma had lower estrogen levels compared to animals with other carcinoma subtypes [16]. An involvement of P4 in mammary tumorigenesis was also suggested, because treatment with progestins increased the risk of CMT [1921], which is probably due to up-regulation of local GH production within the gland [22]. However, no significant differences in endogenously derived P4 serum concentrations were found between bitches with and without mammary neoplasms [17, 18]. A tumorigenic effect of PRL on the mammary tissue was hypothesized, because dogs with CMT had higher PRL levels than healthy animals [17, 23].

Despite the presumed influence of reproductive hormones, studies on endocrine therapy for CMT are rare. Gene or protein expression of ERα (ESR1) and/or ERβ (ESR2), PGR, PRLR and GHR were detected in CMTs, and decreased receptor expression was associated with malignancy and/or a worse prognosis [8, 16, 2432]. Nevertheless, the application of a PGR blocker decreased PGR expression in canine mammary carcinoma cells and reduced cell proliferation in vivo and cell viability in vitro [33, 34]. The selective ER modulator tamoxifen, which is part of the standard therapy for women with ER-positive breast cancer [3537], is not recommended in dogs due to its partial agonistic potential and the associated side effects [38, 39]. Lowering PRL serum levels by oral application of the dopamine receptor agonist cabergoline reduced the size of certain mammary lesions in 25 % of clinically pseudopregnant dogs presenting with mammary tumors [40].

Markers of tumor invasion are used in human medicine to estimate survival time and prognosis [41]. E-cadherin, the product of the CDH-1 gene, is expressed on the surface of most epithelial cells and regulates cell-cell adhesion. In women, loss or down-regulation of CDH-1 in breast carcinoma is associated with shorter survival time [4244]. Similarly, in dogs, reduced immunostaining for CDH-1 is correlated with increased invasion potential, lymph node metastasis, histological grade and infiltration [4548].

Mastectomy is regarded as the most effective treatment for CMT so far. However, further therapeutic options should be sought, which could be used in combination with surgery or in cases of non-operable lesions and inflammatory mammary carcinomas. Knowledge of the interplay between hormones and their receptors during the reproductive cycle, after spaying or during tumorigenesis, could provide a basis for new and advanced therapeutic approaches for dogs with CMT.

Up to now, there is no information on the effect of serum steroid hormone and PRL levels on their respective receptor gene expression in normal and neoplastic mammary tissues in dogs. Our goal was, therefore, to study the associations between circulating serum concentrations of E2, P4 and PRL, and the expression of genes encoding for their respective receptors, i.e., ERα (ESR1), ERβ (ESR2), PGR, PRLR, PRL, as well as GHR, in normal mammary tissues as well as in mammary neoplasms in female dogs, taking into account their reproductive state and cycle stage. Furthermore, gene expression of CDH-1 was analyzed as a marker for tumor invasiveness in mammary tissues showing different degrees of malignancy. In addition, the influence of reproductive state and cycle stages were assessed for all parameters.

Methods

Animals, tissues

A prospective study was carried out with 32 privately owned female dogs that were presented with mammary neoplasms to the Clinic of Reproductive Medicine, Vetsuisse Faculty in Zurich between 2009 and 2013. Altogether, 56 mammary neoplasms and 28 normal mammary tissue samples were collected from these patients. Eleven dogs had only one mammary neoplasm and 21 bitches had two or more lesions. Mastectomy was performed in 28 dogs to remove the masses. The following surgery techniques were used: unilateral mastectomy (n = 12), unilateral mastectomy combined with regional mastectomy (n = 3), regional mastectomy (n = 11), excisional biopsy (n = 2). Three of four dogs with inoperable cancer were euthanized at initial presentation because of their poor general condition. The fourth dog was euthanized two months later because of severe dyspnea due to pulmonary metastasis.

The phase of the estrous cycle at presentation was determined based on history, clinical examination and blood hormone assays (P4 and E2).

All owners consented to their animal becoming a research participant and animal experimentation was approved by the Cantonal Veterinary Authority in Zurich, Switzerland (permission No. 136/2009 and 165/2012).

Blood sampling and hormone analysis

In order to account for the possible pulsatile release and circadian rhythm of PRL secretion [49, 50], two blood samples were collected 30 min apart and always in the morning from each dog prior to surgery or before euthanasia. Samples were centrifuged after clotting, and serum was stored at −20 °C until hormone analysis.

Serum PRL concentrations were measured with a previously validated heterologous radioimmunoassay (RIA) [51]. The intra-assay coefficient of variation was 3.5 %, and the lower limit of detection was 0.8 ng/ml. All serum samples were analyzed in the same run. The mean of the two PRL concentrations from each dog was used for statistical analysis.

E2 and P4 were determined from the first serum sample. E2 concentrations were determined by a solid-phase 125I-RIA (Count-A-Count TKE; Siemens Medical Solution Diagnostics, Los Angeles, CA, USA) according to the manufacturer’s instructions, with slight modifications as described previously and validated for the dog [52, 53]. The intra-assay coefficient of variation was 14 %, and the lower limit of detection was 1.9 pg/ml. Serum P4 concentrations were measured with a previously validated 3H-RIA [51, 54]. The intra- and inter-assay coefficients of variation were 11 and 9.7 %, respectively, and the lower limit of detection was 0.04 ng/ml.

Tissue collection, histopathological classification and sample processing

Neoplastic and normal mammary tissue samples from each dog were collected by surgical mastectomy, biopsy or immediately post mortem. Tissue samples were fixed in 10 % buffered formalin for 24 h and embedded in paraffin. Sections from each block were stained with hematoxylin and eosin (HE) for histopathological diagnosis according to the criteria of Goldschmidt [55], and then grouped as normal mammary tissue, or benign or malignant mammary neoplasms.

The experimental procedure was based on our previously established protocol [25]. Thus, on the HE stained slides, representative parts of mammary neoplasms and normal mammary tissue from each dog were identified and marked. These parts were identified in the original paraffin blocks, cut out manually and re-embedded separately in paraffin. Consecutive sections from these new paraffin blocks were cut using a rotary microtome (RM 2165, Leica, Wetzlar, Germany). The first section (3 μm thick) was used for control HE staining, the following sections (10 μm thick) for RNA extraction (see below), and the last section (3 μm thick) for another control HE staining. The number of sections cut for RNA extraction varied from 15 to 30 depending on neoplasm size. The first and last control HE sections were compared to the selected representative part of the mammary tissue sample. If the control slides did not match the selected tissue, the original paraffin block was re-sampled and re-embedded as described above until both control slides matched the selected area.

RNA extraction and semi-quantitative real-time (TaqMan) PCR

Excess paraffin was manually removed from each representative tissue section in a warm water bath (37 °C), and all sections were transferred into a 1.5 ml plastic Eppendorf tube (Eppendorf, Hamburg, Germany). Total RNA was extracted using the RNeasy FFPE Kit (Qiagen, Hombrechtikon, Switzerland) according to the manufacturer’s instructions. The RNA concentration was measured with a NanoDrop 2000 UV–Vis  Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). The RNA quality was assessed by checking the RNA integrity numbers (RIN) and samples with similar RIN were used for all groups. Extracted RNA was stored at −80 °C until analysis.

In order to remove genomic DNA contamination, 50 ng RNA per reaction was DNAse treated (RQ1 RNase-free DNase, Promega, Dübendorf, Switzerland) in accordance with the manufacturer’s instructions. Afterwards, RNA was reverse transcribed into complementary DNA (cDNA) using Sensiscript Reverse Transcriptase (Qiagen) and random hexamers (Applied Biosystems, Foster City, CA, USA) as primers according to the manufacturer’s instructions. All reactions were carried out in an Eppendorf Mastercycler (Vaudaux-Eppendorf AG, Basel, Switzerland).

Semi-quantitative real-time (TaqMan) PCR reactions for ERα (ESR1), ERβ (ESR2), PGR, PRL, PRLR, GHR and CDH-1 were performed as described previously [56, 57] using three independent endogenous reference genes (canine GAPDH, 18SrRNA and cyclophilin A) in the comparative CT method (ΔΔCT method). Samples were run in duplicates on a 96-well optical plate using an automated fluorometer ABI 7500 Fast Real Time PCR System (Applied Biosystems). Per reaction, 6.25 μl Fast Start Universal Probe Master (ROX) (Roche Diagnostics, Rotkreuz, Switzerland), 300 nM of each primer, 200 nM TaqMan probe, 1.75 μl autoclaved water, and 2.5 μl of 50 ng RNA were used as the TaqMan PCR reaction mixture. Amplification was performed by denaturation for 10 min at 95 °C, 40 cycles at 95 °C for 15 sec and 60 sec at 60 °C. Autoclaved water and the RT minus control were used as negative controls. The sequences of the primers and the 6-carboxyfluorescein (6-FAM) and 6-carboxytetramethyl-rhodamine (TAMRA) labeled TaqMan probes were designed using Primer Express Software (Version 2.0, Applied Biosystems) and are listed in Table 1. All primers and probes were purchased from Microsynth (Microsynth AG, Balgach, Switzerland). The canine–specific TaqMan Gene Expression Assay of Cyclophilin A (Prod. No. Cf03986523-gH), GHR (Prod No. Cf02623459_m1) and CDH-1 (Prod. No. Cf02624268_m1) were purchased from Applied Biosystems. The specificity of selected PCR products for each gene was confirmed by commercial sequencing (Microsynth).
Table 1

List of primers and TaqMan probes used for the semi-quantitative real-time (TaqMan) PCR

Primer

Accession number

Primer sequence

Product length (bp)

ERα (ESR1)

XM533454

Forward: 5’-CCC ATG GAG GAG ACA AAC CA-3’,

93

Reverse: 5’-CCC TGC CTC CTC GGT GAT ATA-3’

TaqMan probe: 5’-CAC GGG CCC AAC TTC ATC ACA TTC-3’

ERβ (ESR2)

XM861041

Forward: 5’-CCC AGC ACG CCC TTC A-3’

78

Reverse: 5’-AAT CAT ATG CAC GAG TTC CTT GTC-3’

TaqMan probe: 5’-CCT CCA TGA TGA TGT CCC TGA CC-3’

GAPDH

AB028142

Forward: 5’-GCT GCC AAA TAT GAC GAC ATC-3’

75

Reverse: 5’-GTA GCC CAG GAT GCC TTT GAG-3’

TaqMan probe: 5’-TCC CTC CGA TGC CTG CTT CAC TAC CTT-3’

PGR

NM_001003074

Forward: 5’-CGA GTC ATT ACC TCA GAA GAT TTG TTT-3’

113

Reverse: 5’-CTT CCA TTG CCC TTT TAA AGA AGA-3’

TaqMan probe: 5’-AAG CAT CAG GCT GTC ATT ATG GTG TCC TAA CTT-3’

PRL

NM_00108275

Forward: 5’-CAA GCC CAA CAG ATC CAC CAT-3’

104

Reverse: 5’-ATC CCC CGC ACT TCT GTG A-3’

TaqMan probe: 5’-CTG AGG GTG CTG CGC TCC TGG-3’

PRLR

HQ267784

Forward: 5’-GGA TCT TTG TTG CCG TTC TTT -3’

92

Reverse: 5’-AAG GAT GCA GGT CAC CAT GCT AT-3’

TaqMan probe: 5’-ATT ATG GTC GTA GCA GTG GCT TTG AAA GGC-3’

18SrRNA

FJ797658

Forward: 5’-GTC GCT CGC TCC TCT CCT ACT-3’

125

Reverse: 5’-GGC TGA CCG CCT TGG TTT-3’

TaqMan probe: 5’-ACA TGC CGA CGG GCG CTG AC-3’

Statistical analysis

Raw data are presented as the mean and standard deviation (SD). A t-test was performed to compare serum hormone levels of dogs in different reproductive states and cycle stages. The statistical software “R” version 3.0.2 [58] and the package “nlme” [59] were used for the analysis of different statistical models with receptor gene expression as the outcome variable. Due to the repeated measurements per animal, linear mixed-effects models were applied. Animal was taken as a random effect. For the analysis of receptor gene expression in mammary tissue, outcome variables of PRLR, PGR, ERα (ESR1) and ERβ (ESR2) were used with the following predictor variables in the models: corresponding hormones of PRL, P4, E2; tissue group with the categories normal, benign, malignant; reproductive state and/or cycle with the categories spayed, anestrous, diestrous. Additionally, interactions between tissue group and hormone levels were evaluated. For the outcome variables GHR and CDH-1, the following predictor variables were tested: tissue group (normal, benign, malignant), reproductive state and/or cycle stage (spayed, anestrous, diestrous). For GHR and CDH-1, interactions between tissue group and reproductive state and/or cycle stage were also analyzed. Model selection was based on the Akaike information criterion (AIC) with lower values indicating a better model fit. A difference of at least −2 was considered as indicative of a better model fit. If AIC values differed by less than 2, the model with the lowest number of predictors was chosen (principle of parsimony). Results of the linear mixed effect models are given as p-values and effect size with their standard errors (SE). A p < 0.05 was considered significant.

Results

Animals and neoplasm classification

The ages of dogs at the time of blood and tissue sampling ranged from 4.6 to 16.4 years (mean ± SD, 9.8 ± 2.69). Bitches were of different breeds, the most frequent being mixed breed dogs (n = 9), Jack Russell terriers (n = 3), Boxers (n = 2) and dachshunds (n = 2).

Twenty-four bitches were intact, of which 13 were in anestrus and 11 in diestrus. Eight dogs had been previously spayed before the time of mastectomy, six between the ages of 7 and 10 years, one before 18 months of age, and in one dog no information was available.

The group of benign mammary neoplasms consisted of 19 tissue samples out of 12 dogs, the malignant neoplasia group of 37 samples from 24 dogs. Benign neoplasms included complex adenomas (n = 10), simple adenomas (n = 6), mixed benign mammary tumors (n = 2) and one ductal adenoma. The malignant group consisted of complex carcinomas (n = 14), simple carcinomas (n = 12), anaplastic carcinomas (n = 3), solid carcinomas (n = 3), ductal carcinomas (n = 3), one adeno-squamous carcinoma, and one carcinoma and malignant myoepithelioma. Normal tissue was available from 28 dogs.

Hormonal analysis and gene expression

Serum levels of E2, P4 and PRL varied between 0.52 and 16.32 pg/ml, 0.05 and 91.4 ng/ml, and 1.32 and 8.91 ng/ml, respectively (Table 2). Serum for E2 measurement was not available from two dogs that were both affected by simple adenomas.
Table 2

Serum E2, P4 and PRL concentrations in dogs with mammary neoplasms

 

E2 (pg/ml)

P4 (ng/ml)

PRL (ng/ml)

all dogs (n = 32)

7.85 ± 4.70

9.57 ± 21.50

3.97 ± 1.92

  spayed (n = 8)

2.35 ± 1.12a

0.30 ± 0.27

2.97 ± 1.16b

  intact (n = 24)

9.85 ± 3.79a

12.67 ± 24.14

4.31 ± 2.02b

  anestrous (n = 13)

8.09 ± 4.08c

0.47 ± 0.40d

3.99 ± 2.13

  diestrous (n = 11)

11.95 ± 2.05c

27.08 ± 30.31d

4.69 ± 1.90

Values are shown as mean ± SD. Same superscripts within a column denote significant differences at p < 0.05 (assessed with a t-test).

Gene expression of ERα (ESR1), PGR, PRLR, GHR and CDH-1 was detected in normal mammary tissues and in all mammary neoplasms, except in one carcinoma. The PRL and ERβ (ESR2) mRNA expression was below the detection limit in most of the samples in all groups, revealing more negative than positive results and, thereby, indicating their low expression levels. Corpus luteum tissue (mid-diestrus) used as a positive control tested positively for both factors (Additional file 1 (1.2)).

Regarding gene expression of reproductive hormone receptors, the best predictor variable tested was “tissue group” for ERα (ESR1) (p = 0.03), PGR (p = 0.008) and PRLR (p = 0.001). Thus, malignant tumors showed significantly lower ERα (ESR1) and PGR gene expression than normal mammary tissues (p = 0.017 and p = 0.002, respectively; Fig. 1A and B). PRLR mRNA expression was significantly lower in both benign and malignant mammary neoplasms than in normal tissues (p = 0.009 and p < 0.001, respectively) with lowest values detected in the malignant group (Fig. 1C).
Fig. 1

Model results of relative gene expression (fold changes in mRNA levels, mean ± SE) of A ERα (ESR1), B PGR, C PRLR and D GHR in normal mammary tissue, benign and malignant neoplasms. The significant interaction for tissue group and reproductive state/cycle on CDH-1 gene expression is shown in (E,F); E Relative gene expression (RGE; fold changes in mRNA levels, mean ± SE) of CDH-1 in normal mammary tissue, benign and malignant mammary neoplasms of diestrous dogs; F Relative gene expression (RGE; fold changes in mRNA levels, mean ± SE) of CDH-1 in benign mammary neoplasms collected from spayed dogs, anestrous and diestrous bitches. Bars with different superscripts differ at p < 0.05

Out of the models containing “hormone blood level” and “tissue group” a relationship was only found for PRLR mRNA expression: PRL blood levels had a negative relationship with PRLR gene expression only in malignant neoplasms (p = 0.025). In contrast to these finding, the corresponding models for PGR and ERα (ESR1) did not show a relationship with their hormone levels (p = 0.07 and p = 0.11, respectively).

GHR gene expression was also predicted best by “tissue group” (p = 0.008). Consequently, GHR mRNA levels were significantly lower in malignant neoplasms compared to normal mammary tissue (p = 0.003; Fig. 1D).

In all other models, i.e., those using the predictors variable blood level, reproductive state and/or cycle stage, as well as the interaction between tissue group and reproductive state/cycle stage variables, were not significantly associated with receptor expression.

In contrast to the expressions of reproductive hormone receptors, the gene expression for CDH-1 revealed a significant interaction (p = 0.012) for both “tissue group and reproductive state and/or cycle stage”. Among diestrous bitches, CDH-1 gene expression was highest in benign neoplasms compared to normal mammary tissue and malignant neoplasms (p = 0.001 and p = 0.008, respectively; Fig. 1E). However, no such differences were found between samples collected in other reproductive states or cycle stages, either in spayed animals (p = 0.63 and p = 0.89, respectively) or in anestrous dogs (p = 0.09 and p = 0.09, respectively). Analyzing mammary samples according to “tissue group”, benign neoplasms from diestrous bitches expressed significantly higher levels of CDH-1 mRNA than benign neoplasms from spayed or anestrous dogs (p = 0.003 and p = 0.026, respectively; Fig. 1F). CDH-1 gene expression in malignant neoplasms and in normal mammary tissue was similar between diestrous and spayed (p ≥ 0.23), and between diestrous and anestrous dogs (p ≥ 0.33). The AIC values of models, which tested the relationship between the expression of CDH-1 and E2, P4, or PRL levels were higher than those determined for the model describing the expression of CDH-1 gene in dependence of tissue group and reproductive status/cycle stage. Thus, hormone levels had no influence on CDH-1 expression in our study.

Detailed information on hormone levels, reproductive states and cycle stages, and relative gene expression of receptors detected in normal tissues and/or mammary tumors per dog are presented in the Additional file 1 (1.1).

Discussion

Growth of mammary epithelial cells is stimulated by steroid hormones [60, 61], PRL [62] and GH [7]. In dogs, most studies showed lower ERα (ESR1) as well as PGR expression in malignant compared to benign mammary tumors [29, 31, 63] or normal mammary tissue [16, 30, 29]. A tendency for decreased GHR expression was also noted, particularly in undifferentiated carcinomas [7, 8], which showed heterogeneous immunoreactivity compared to diffuse staining in normal tissue and benign tumors [8]. These studies are in accordance with our findings of decreased mRNA expression of ERα (ESR1) and PGR in malignant CMTs compared to normal tissue, although benign neoplasms were not different in these respects from either malignant or normal samples. The loss of or decreased receptor expression may be indicative of increasing resistance to hormonal stimulatory effects [64], and might serve as an indicator of malignancy as suggested before [8, 16, 2931, 63].

The possible influence of steroid hormone levels on mammary tumors in dogs was previously investigated [1618]. Thus, higher E2 concentrations were found both in serum as well as in tissue homogenates in cases of non-inflammatory malignant neoplasms compared to normal mammary tissue [1618] or to benign tumors [17]. P4 levels showed a similar trend but only in tissue homogenates [18]. In contrast to these previous studies, which included only intact dogs in anestrus [1618], our animal population represented different reproductive states and cycle stages including diestrous dogs, and various types of mammary tissue samples to take into account the multicentric nature and diversity of CMTs [65]. This approach may include possible effects of a malignant neoplasm on the remaining mammary gland, i.e., altering its gene expression levels or influencing sex steroid and PRL serum levels. However, to gather sufficient information, a much larger data base would be required. Furthermore, to investigate the postulated tumor-promoting effects of sex hormones during early carcinogenesis, longitudinal data would be desirable.

All of the above-cited studies evaluated either expression patterns of the respective hormone receptors, or the hormonal status of diseased dogs, and/or the local hormonal status of tumors. However, the association between these entities within one animal population has never been studied before. Consequently, the present study was initiated to establish such possible relationships. Based on the results presented herein, we infer that neoplasm type is the primary determinant of canine mammary steroid hormone receptor gene expression while other factors, including circulating steroid hormone serum concentrations, reproductive state and cycle stage, as well as interactions among the above, seem to have little or no influence. This is not surprising, because most dogs affected by mammary cancer have multiple lesions of different histological types [55, 66, 67]. Therefore, we intentionally included more than one neoplasm per dog when several lesions were present, and took the animal as a random factor into account in the statistical analyses as this best represented the affected dog population.

Considering the lack of the effect of the reproductive status and/or cycle stage, and thereby, of the hormonal status on the respective hormone receptor expression, this could be due to the physiological high variation of hormonal levels in dogs, overlapping with the limited number of samples used for our study, and the possible breed effects.

The PRL-PRLR complex plays a role in mammary tumorigenesis, as shown, e.g., in human breast cancer [68]. In agreement with our previous study [25], we detected decreasing PRLR gene expression levels during the course of malignant transformation, i.e., from normal mammary tissue towards benign and further to malignant transformation [25]. However, in that previous study, the reproductive state of the dogs was unknown, serum hormone levels were not investigated and CMTs consisted of a more homogeneous group of adenomas and adenocarcinomas. In the present study, we found increased serum PRL levels in malignant CMTs, which were associated with low PRLR gene expression. Similarly, high PRL concentrations in serum and tissue homogenates were previously shown in dogs suffering from malignant tumors [17, 23]. One possible explanation for these findings is that high levels of PRL induced down-regulation of PRLR transcription in the mammary gland. This could be a sign of loss of differentiation in the neoplastic cells, in which case PRL would have little or no effect in these malignant neoplasms. PRL is known to modulate the availability of its own receptor by stimulating its proteolytic degradation. This impaired PRLR turnover, which leads to its stabilization and accumulation, presumably increases the magnitude and duration of PRL signaling and contributes to transformation of human mammary epithelial cells [69, 70].

As indicated above, in dogs as in humans, PRL can be produced not only in the anterior pituitary, but also in normal mammary tissue and malignant mammary tumors [17, 23, 7173]. Moreover, higher tissue PRL levels were observed by Queiroga and colleagues in CMT homogenates [17, 23]. Consequently, the autocrine/paracrine loop of mammary PRL-PRLR complex [7173] contributing to human breast cancer development [74] has also been implied for the dog [17, 75]. Contrasting with these previous findings, in the present study the local expression of PRL mRNA was below detection limits in the canine mammary gland. However, mRNA concentrations might not always reflect the actual PRL concentrations at the protein level.

The activation of PRLR by PRL results in signaling through the Jak2/Stat5a pathway. Stat5 activation initiates cell differentiation through expression of the CDH-1-β-catenin complex [76, 77], which may suggest a protective effect of PRL against neoplasm formation, because decreased Stat5a activation was associated with metastatic progression in human breast cancer [78]. At present, it is still not clear whether PRL acts as a promoter or a suppressor of neoplasm development or as a promoter of differentiation [7982]. Nevertheless, reduced immunohistochemical expression of CDH-1 in the mammary gland was related to malignancy, invasive growth, lymph node metastasis, necrosis, differentiation grade, size and ulceration of the tumor in dogs [4548, 83]. There is limited knowledge on the molecular mechanisms behind CDH-1 down-regulation in CMTs, and about when it occurs during neoplastic progression. Pardini and colleagues [84] showed decreased CDH-1 mRNA expression in dogs with mammary carcinoma compared to normal tissue. We could not confirm this finding, as in our study similar mRNA concentrations were detected in normal mammary tissue and in malignant neoplasms. However, modifications in post-translational N-glycosylation of CDH-1 [85] cannot be ruled out, which may result in decreased cell-cell adhesion in the malignant lesions. Interestingly, we found increased CDH-1 gene expression in benign compared to malignant neoplasms, which supports the role of CDH-1 as a marker for cell differentiation. This is in line with the lack of metastatic and invasive properties of benign neoplasms. The highest CDH-1 mRNA levels were seen in benign lesions during the diestrus phase, which may be attributed to the effects of P4. Similarly, CDH-1 gene expression was up-regulated in the canine uterus under P4 treatment and during pregnancy [86]. In contrast to our expectations, reproductive state or cycle stage had no effect on CDH-1 mRNA levels in normal mammary tissue. This could be, however, due to the source of the normal/healthy tissue used for the present study, which was collected from dogs affected by mammary tumors. The microenvironment of malignant mammary tumor could have a modulatory effect on the expression of CHD-1.

Conclusion

The transformation from a normal to a malignant phenotype was associated with a significant loss of ERα (ESR1), PGR, GHR and PRLR gene expression in the mammary tissue of dogs. Only PRLR gene expression was significantly decreased concurrently with the formation of benign tumors. Increased levels of serum PRL, but not of P4 and E2, were associated with a decrease in gene expression of the respective receptors only in malignant mammary neoplasms. No evidence was found for the presence of a paracrine/autocrine action of PRL in the canine mammary gland. CDH-1 mRNA expression was higher in benign compared to malignant neoplasms and normal mammary tissue and thus may serve as a prognostic marker.

Notes

Abbreviations

HE: 

hematoxilin and eosin

RIN: 

RNA integrity numbers

RGE: 

relative gene expression

CMT: 

Canine mammary tumors

P4: 

Progesterone

PGR: 

Progesterone receptor

E2: 

Estradiol 17β

ERα (ESR1): 

Estrogen receptor α

ERβ (ESR2): 

Estrogen receptor β

PRL: 

Prolactin

PRLR: 

Prolactin receptor

GH: 

Growth hormone

GHR: 

Growth hormone receptor

CDH-1: 

E-cadherin

RIA: 

Radioimmunoassay

Declarations

Acknowledgements

Authors are grateful to Dr. Barry Bavister for careful editing of the manuscript. The competent technical assistance of Elisabeth Högger is greatly appreciated.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Clinic of Reproductive Medicine, Vetsuisse Faculty University of Zurich
(2)
Institute of Veterinary Anatomy, Vetsuisse Faculty University of Zurich
(3)
Institute of Veterinary Pathology, Vetsuisse Faculty University of Zurich
(4)
Section of Epidemiology, Vetsuisse Faculty
(5)
Department of Animal Health, Faculty of Veterinary Medicine, Utrecht University
(6)
Division of Animal Anatomy, Department of Animal Physiology and Biostructure, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences

References

  1. Silberstein GB. Postnatal mammary gland morphogenesis. Microsc Res Tech. 2001;52(2):155–62. doi:10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
  2. Sorenmo KU, Rasotto R, Zappulli V, Goldschmidt MH. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol. 2010;48(1):85–97. doi:10.1177/0300985810389480.View ArticlePubMedGoogle Scholar
  3. Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL, Weinberg RA, et al. Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol. 1999;210(1):96–106. doi:10.1006/dbio.1999.9271.View ArticlePubMedGoogle Scholar
  4. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24(1):1–27.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Rehm S, Stanislaus DJ, Williams AM. Estrous cycle-dependent histology and review of sex steroid receptor expression in dog reproductive tissues and mammary gland and associated hormone levels. Birth Defects Res B Dev Reprod Toxicol. 2007;80(3):233–45. doi:10.1002/bdrb.20121.View ArticlePubMedGoogle Scholar
  6. Chandra SA, Mark Cline J, Adler RR. Cyclic morphological changes in the beagle mammary gland. Toxicol Pathol. 2010;38(6):969–83. doi:10.1177/0192623310374327.View ArticlePubMedGoogle Scholar
  7. van Garderen E, Schalken JA. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol Cell Endocrinol. 2002;197(1–2):153–65. doi:10.1016/S0303-7207(02)00259-9.View ArticlePubMedGoogle Scholar
  8. van Garderen E, van der Poel HJ, Swennenhuis JF, Wissink EH, Rutteman GR, Hellmen E, et al. Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. Endocrinology. 1999;140(12):5907–14. doi:10.1210/endo.140.12.7189.View ArticlePubMedGoogle Scholar
  9. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst. 1969;43(6):1249–61.PubMedGoogle Scholar
  10. Beauvais W, Cardwell JM, Brodbelt DC. The effect of neutering on the risk of mammary tumours in dogs-a systematic review. J Small Anim Pract. 2012;53(6):314–22. doi:10.1111/j.1748-5827.2011.01220.x.View ArticlePubMedGoogle Scholar
  11. Kristiansen VM, Nodtvedt A, Breen AM, Langeland M, Teige J, Goldschmidt M, et al. Effect of ovariohysterectomy at the time of tumor removal in dogs with benign mammary tumors and hyperplastic lesions: a randomized controlled clinical trial. J Vet Intern Med. 2013;27(4):935–42. doi:10.1111/jvim.12110.View ArticlePubMedGoogle Scholar
  12. Chang SC, Chang CC, Chang TJ, Wong ML. Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998–2002). J Am Vet Med Assoc. 2005;227(10):1625–9.View ArticlePubMedGoogle Scholar
  13. Sorenmo KU, Shofer FS, Goldschmidt MH. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. J Vet Intern Med. 2000;14(3):266–70.View ArticlePubMedGoogle Scholar
  14. Yamagami T, Kobayashi T, Takahashi K, Sugiyama M. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. J Small Anim Pract. 1996;37(10):462–4.View ArticlePubMedGoogle Scholar
  15. Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW, Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med. 2003;17(1):102–6.View ArticlePubMedGoogle Scholar
  16. Illera JC, Perez-Alenza MD, Nieto A, Jimenez MA, Silvan G, Dunner S, et al. Steroids and receptors in canine mammary cancer. Steroids. 2006;71(7):541–8. doi:10.1016/j.steroids.2005.11.007.View ArticlePubMedGoogle Scholar
  17. Queiroga FL, Perez-Alenza MD, Silvan G, Pena L, Lopes C, Illera JC. Role of steroid hormones and prolactin in canine mammary cancer. J Steroid Biochem Mol Biol. 2005;94(1–3):181–7. doi:10.1016/j.jsbmb.2004.12.014.View ArticlePubMedGoogle Scholar
  18. Sanchez-Archidona AR, Jimenez MA, Perez-Alenza D, Silvan G, Illera JC, Pena L, et al. Steroid pathway and oestrone sulphate production in canine inflammatory mammary carcinoma. J Steroid Biochem Mol Biol. 2007;104(3–5):93–9. doi:10.1016/j.jsbmb.2007.03.014.View ArticlePubMedGoogle Scholar
  19. Giles RC, Kwapien RP, Geil RG, Casey HW. Mammary nodules in beagle dogs administered investigational oral contraceptive steroids. J Natl Cancer Inst. 1978;60(6):1351–64.PubMedGoogle Scholar
  20. Concannon PW, Spraker TR, Casey HW, Hansel W. Gross and histopathologic effects of medroxyprogesterone acetate and progesterone on the mammary glands of adult beagle bitches. Fertil Steril. 1981;36(3):373–87.PubMedGoogle Scholar
  21. Stovring M, Moe L, Glattre E. A population-based case–control study of canine mammary tumours and clinical use of medroxyprogesterone acetate. APMIS. 1997;105(8):590–6.View ArticlePubMedGoogle Scholar
  22. Selman PJ, Mol JA, Rutteman GR, van Garderen E, Rijnberk A. Progestin-induced growth hormone excess in the dog originates in the mammary gland. Endocrinology. 1994;134(1):287–92. doi:10.1210/endo.134.1.7506206.PubMedGoogle Scholar
  23. Queiroga FL, Perez-Alenza MD, Gonzalez Gil A, Silvan G, Pena L, Illera JC. Clinical and prognostic implications of serum and tissue prolactin levels in canine mammary tumours. Vet Rec. 2014;175(16):403. doi:10.1136/vr.102263.View ArticlePubMedGoogle Scholar
  24. de Las Mulas JM, Millan Y, Dios R. A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol. 2005;42(2):200–12. doi:10.1354/vp.42-2-200.View ArticlePubMedGoogle Scholar
  25. Michel E, Feldmann SK, Kowalewski MP, Bley CR, Boos A, Guscetti F, et al. Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas. BMC Vet Res. 2012;8:72. doi:10.1186/1746-6148-8-72.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Geraldes M, Gartner F, Schmitt F. Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumours. Vet Rec. 2000;146(14):403–6.View ArticlePubMedGoogle Scholar
  27. Rutteman GR, Misdorp W, Blankenstein MA, van den Brom WE. Oestrogen (ER) and progestin receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and malignant states. Br J Cancer. 1988;58(5):594–9.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Rutteman GR, Willekes-Koolschijn N, Bevers MM, Van der Gugten AA, Misdorp W. Prolactin binding in benign and malignant mammary tissue of female dogs. Anticancer Res. 1986;6(4):829–35.PubMedGoogle Scholar
  29. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci. 2005;79(3):225–32. doi:10.1016/j.rvsc.2005.02.002.View ArticlePubMedGoogle Scholar
  30. Chang CC, Tsai MH, Liao JW, Chan JP, Wong ML, Chang SC. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. J Am Vet Med Assoc. 2009;235(4):391–6. doi:10.2460/javma.235.4.391.View ArticlePubMedGoogle Scholar
  31. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM, Castano M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol. 2000;37(3):239–47.View ArticlePubMedGoogle Scholar
  32. Pawlowski KM, Popielarz D, Szyszko K, Gajewska M, Motyl T, Krol M. Growth hormone receptor (GHR) RNAi decreases proliferation and enhances apoptosis in CMT-U27 canine mammary carcinoma cell line. Vet Comp Oncol. 2012;10(1):2–15. doi:10.1111/j.1476-5829.2011.00269.x.View ArticlePubMedGoogle Scholar
  33. Guil-Luna S, Sanchez-Cespedes R, Millan Y, De Andres FJ, Rollon E, Domingo V, et al. Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas. J Vet Intern Med. 2011;25(3):518–23. doi:10.1111/j.1939-1676.2011.0723.x.View ArticlePubMedGoogle Scholar
  34. Guil-Luna S, Hellmen E, Sanchez-Cespedes R, Millan Y, Martin De Las Mulas J. The antiprogestins mifepristone and onapristone reduce cell proliferation in the canine mammary carcinoma cell line CMT-U27. Histol Histopathol. 2014;29(7):949–55. doi:HH-11-454.PubMedGoogle Scholar
  35. Stuart-Harris R, Davis A. Optimal adjuvant endocrine therapy for early breast cancer. Womens Health (Lond Engl). 2010;6(3):383–98. doi:10.2217/whe.10.25.View ArticleGoogle Scholar
  36. Group EBCTC. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med. 1988;319(26):1681–92. doi:10.1056/NEJM198812293192601.View ArticleGoogle Scholar
  37. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;97(5 Pt 2):855–66. doi:S0029784400011960.View ArticlePubMedGoogle Scholar
  38. Morris JS, Dobson JM, Bostock DE. Use of tamoxifen in the control of canine mammary neoplasia. Vet Rec. 1993;133(22):539–42.View ArticlePubMedGoogle Scholar
  39. Tavares WL, Lavalle GE, Figueiredo MS, Souza AG, Bertagnolli AC, Viana FA, et al. Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet Scand. 2010;52:67. doi:10.1186/1751-0147-52-67.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Verstegen JP, Onclin K. Prolactin and anti-prolactin agents in the pathophysiology and treatment of mammary tumors in the dog. Orlando, FL: The North American Vetrinary Conference; 2006.Google Scholar
  41. Foo EM, Boost MV, Wong AS, Loo WT, Chow LW, Chow CY. New developments in breast cancer prognosis: molecular predictors of treatment response and survival. Int J Biol Markers. 2013;28(2):131–40. doi:10.5301/jbm.5000027.View ArticlePubMedGoogle Scholar
  42. Guriec N, Marcellin L, Gairard B, Calderoli H, Wilk A, Renaud R, et al. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival. Invasion Metastasis. 1996;16(1):19–26.PubMedGoogle Scholar
  43. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology. 1999;34(1):25–34.View ArticlePubMedGoogle Scholar
  44. Asgeirsson KS, Jonasson JG, Tryggvadottir L, Olafsdottir K, Sigurgeirsdottir JR, Ingvarsson S, et al. Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance. Eur J Cancer. 2000;36(9):1098–106. doi:S0959804900000629.View ArticlePubMedGoogle Scholar
  45. Restucci B, Papparella S, De Vico G, Maiolino P. E cadherin expression in normal and neoplastic canine mammary gland. J Comp Pathol. 1997;116(2):191–202.View ArticlePubMedGoogle Scholar
  46. Reis AL, Carvalheira J, Schmitt FC, Gartner F. Immunohistochemical study of the expression of E-cadherin in canine mammary tumours. Vet Rec. 2003;152(20):621–4.View ArticlePubMedGoogle Scholar
  47. Gama A, Paredes J, Gartner F, Alves A, Schmitt F. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Vet J. 2008;177(1):45–53. doi:10.1016/j.tvjl.2007.05.024.View ArticlePubMedGoogle Scholar
  48. Matos AJ, Lopes C, Carvalheira J, Santos M, Rutteman GR, Gartner F. E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables. J Comp Pathol. 2006;134(2–3):182–9. doi:10.1016/j.jcpa.2005.10.004.View ArticlePubMedGoogle Scholar
  49. Corrada Y, Castex G, Sosa Y, Gobello C. Secretory patterns of prolactin in dogs: circannual and ultradian rhythms. Reprod Domest Anim. 2003;38(3):219–23. doi:10.1046/j.1439-0531.2003.00432.x.View ArticlePubMedGoogle Scholar
  50. Gobello C, Bolognani F, de la Sota RL, Goya RG. Twenty-four-hour profiles of serum prolactin and luteinizing hormone in anoestrous crossbred bitches. Reprod Domest Anim. 2001;36(1):41–5.View ArticlePubMedGoogle Scholar
  51. Okkens AC, Dieleman SJ, Bevers MM, Willemse AH. Evidence for the non-involvement of the uterus in the lifespan of the corpus luteum in the cyclic dog. Vet Q. 1985;7(3):169–73. doi:10.1080/01652176.1985.9693978.View ArticlePubMedGoogle Scholar
  52. Dieleman SJ, Bevers MM. Effects of monoclonal antibody against PMSG administered shortly after the preovulatory LH surge on time and number of ovulations in PMSG/PG-treated cows. J Reprod Fertil. 1987;81(2):533–42.View ArticlePubMedGoogle Scholar
  53. van Haaften B, Bevers MM, van den Brom WE, Okkens AC, van Sluijs FJ, Willemse AH, et al. Increasing sensitivity of the pituitary to GnRH from early to late anoestrus in the beagle bitch. J Reprod Fertil. 1994;101(1):221–5.View ArticlePubMedGoogle Scholar
  54. Dieleman SJ, Schoenmakers HJ. Radioimmunoassays to determine the presence of progesterone and estrone in the starfish Asterias rubens. Gen Comp Endocrinol. 1979;39(4):534–42.View ArticlePubMedGoogle Scholar
  55. Goldschmidt M, Pena L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol. 2011;48(1):117–31. doi:10.1177/0300985810393258.View ArticlePubMedGoogle Scholar
  56. Kowalewski MP, Schuler G, Taubert A, Engel E, Hoffmann B. Expression of cyclooxygenase 1 and 2 in the canine corpus luteum during diestrus. Theriogenology. 2006;66(6–7):1423–30. doi:10.1016/j.theriogenology.2006.01.039.View ArticlePubMedGoogle Scholar
  57. Kowalewski MP, Meyer A, Hoffmann B, Aslan S, Boos A. Expression and functional implications of peroxisome proliferator-activated receptor gamma (PPARgamma) in canine reproductive tissues during normal pregnancy and parturition and at antiprogestin induced abortion. Theriogenology. 2011;75(5):877–86. doi:10.1016/j.theriogenology.2010.10.030.View ArticlePubMedGoogle Scholar
  58. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. http://www.R-project.org/.Google Scholar
  59. Pinheiro J, Bates D, DebRoby S, Sarkar D. Linear and nonlinear mixed effects models, 2010, R package version 3.1-97. R package version 31–97. 2010.Google Scholar
  60. Murphy LC, Watson P. Steroid receptors in human breast tumorigenesis and breast cancer progression. Biomed Pharmacother. 2002;56(2):65–77.View ArticlePubMedGoogle Scholar
  61. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia. 1998;3(1):23–35.View ArticlePubMedGoogle Scholar
  62. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19(3):225–68.View ArticlePubMedGoogle Scholar
  63. Mainenti M, Rasotto R, Carnier P, Zappulli V. Oestrogen-alpha and progesterone receptor expression in subtypes of canine mammary tumours in intact and ovariectomised dogs. Vet J. 2014. doi:10.1016/j.tvjl.2014.06.003.
  64. Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gartner F, Gruber AD. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol. 2010;48(1):98–116. doi:10.1177/0300985810390826.View ArticlePubMedGoogle Scholar
  65. Ferguson HR. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. 1985;15(3):501–11.View ArticlePubMedGoogle Scholar
  66. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, et al. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol. 2009;7(3):162–72. doi:10.1111/j.1476-5829.2009.00184.x.View ArticlePubMedGoogle Scholar
  67. Fowler EH, Wilson GP, Koestner A. Biologic behavior of canine mammary neoplasms based on a histogenetic classification. Vet Pathol. 1974;11(3):212–29.View ArticlePubMedGoogle Scholar
  68. Clevenger CV. Role of prolactin/prolactin receptor signaling in human breast cancer. Breast Dis. 2003;18:75–86.PubMedGoogle Scholar
  69. Plotnikov A, Varghese B, Tran TH, Liu C, Rui H, Fuchs SY. Impaired turnover of prolactin receptor contributes to transformation of human breast cells. Cancer Res. 2009;69(7):3165–72. doi:10.1158/0008-5472.CAN-08-4033.PubMed CentralView ArticlePubMedGoogle Scholar
  70. Li Y, Clevenger CV, Minkovsky N, Kumar KG, Raghunath PN, Tomaszewski JE, et al. Stabilization of prolactin receptor in breast cancer cells. Oncogene. 2006;25(13):1896–902. doi:10.1038/sj.onc.1209214.View ArticlePubMedGoogle Scholar
  71. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995;55(12):2591–5.PubMedGoogle Scholar
  72. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology. 1997;138(12):5555–60. doi:10.1210/endo.138.12.5605.PubMedGoogle Scholar
  73. Harvey S, Martinez-Moreno CG, Luna M, Aramburo C. Autocrine/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: An overview. Gen Comp Endocrinol. 2014. doi:10.1016/j.ygcen.2014.11.004.
  74. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol. 1995;146(3):695–705.PubMed CentralPubMedGoogle Scholar
  75. Michel E, Rohrer Bley C, Kowalewski MP, Feldmann SK, Reichler IM. Prolactin--to be reconsidered in canine mammary tumourigenesis? Vet Comp Oncol. 2014;12(2):93–105. doi:10.1111/j.1476-5829.2012.00337.x.View ArticlePubMedGoogle Scholar
  76. Sultan AS, Brim H, Sherif ZA. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci. 2008;99(2):272–9. doi:10.1111/j.1349-7006.2007.00685.x.View ArticlePubMedGoogle Scholar
  77. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 2005;24(5):746–60. doi:10.1038/sj.onc.1208203.View ArticlePubMedGoogle Scholar
  78. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004;22(11):2053–60. doi:10.1200/JCO.2004.11.046.View ArticlePubMedGoogle Scholar
  79. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res. 2006;66(3):1824–32. doi:10.1158/0008-5472.CAN-05-2292.View ArticlePubMedGoogle Scholar
  80. Harvey PW. Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J Appl Toxicol. 2012;32(1):1–9. doi:10.1002/jat.1772.View ArticlePubMedGoogle Scholar
  81. Manhes C, Goffin V, Kelly PA, Touraine P. Autocrine prolactin as a promotor of mammary tumour growth. J Dairy Res. 2005;72:58–65.View ArticlePubMedGoogle Scholar
  82. Brockman JL, Schroeder MD, Schuler LA. PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol. 2002;16(4):774–84. doi:10.1210/mend.16.4.0817.View ArticlePubMedGoogle Scholar
  83. De Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Rutteman GR, Gartner MF. E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours. APMIS. 2007;115(4):327–34. doi:10.1111/j.1600-0463.2007.apm_544.x.View ArticlePubMedGoogle Scholar
  84. Pardini LMC, Ranzani JJT, Brandão CVS, Lopes C, Souza PM, Castillo JAL, et al. Relative expression of CDH1 gene in mammary carcinoma in female dogs searching for correlations with ocular and thoracic metastasis. Prague, Czech Republic: The World Congress on Controversies, Debates & Consensus in Veterinary Medicine (CoVet); 2014.Google Scholar
  85. Pinho SS, Osorio H, Nita-Lazar M, Gomes J, Lopes C, Gartner F, et al. Role of E-cadherin N-glycosylation profile in a mammary tumor model. Biochem Biophys Res Commun. 2009;379(4):1091–6. doi:10.1016/j.bbrc.2009.01.024.View ArticlePubMedGoogle Scholar
  86. Guo B, Han BC, Tian Z, Zhang XM, Jiang LX, Liu JX, et al. Expression and hormonal regulation of E-cadherin in canine uterus during early pregnancy. Reprod Domest Anim. 2010;45(6):e255–9. doi:10.1111/j.1439-0531.2009.01550.x.View ArticlePubMedGoogle Scholar

Copyright

© Spoerri et al. 2015

Advertisement